Oppenheimer Starts Syros Pharmaceuticals (SYRS) at Outperform

November 28, 2016 4:07 PM EST
Get Alerts SYRS Hot Sheet
Price: $16.41 -1.44%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 18 | New: 18
Trade SYRS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Oppenheimer initiates coverage on Syros Pharmaceuticals (NASDAQ: SYRS) with a Outperform rating and a price target of $28.00.

Analyst Leah Rush Cann commented, "We are initiating coverage of Syros Pharmaceuticals, a development-stage biotechnology company, with an Outperform rating and 12- to 18-month price target of $28. We estimate Syros could launch its first drug, SY-1425, as early as 2018. Based on our expectation that Syros will launch its first product in the next few years, we assume that the company will have revenue in 2018 and that it will grow at a CAGR of 103% from 2018-21, to $510 million in 2021. However, as it is the case with development-stage companies, these estimates do carry a degree of risk."

For an analyst ratings summary and ratings history on Syros Pharmaceuticals click here. For more ratings news on Syros Pharmaceuticals click here.

Shares of Syros Pharmaceuticals closed at $14.19 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Add Your Comment